Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: Under the agreement, Emergent BioSolutions will no longer enforce a contract that had allowed it to be the only company to develop a nasal spray version of the drug nalmefene for use as an antidote in a nasal spray. The attorney general’s office said the new agreement came after it found that Adapt Pharma, which has since been bought by Rockville, Maryland-based Emergent, had the exclusive rights to sell the drug using Aptar Pharma’s nasal spray technology. The drug is still in the pipeline and is not on the market, though. “Given the tragic, devastating effects of the opioid crisis, and the urgent need for additional drugs for the emergency treatment of opioid overdoses, my office will do whatever possible to ensure that there are no unnecessary impediments to the development of additional life-saving opioid overdose reversal drugs,” Attorney General Letitia James said in a written statement. The agreement with James’s office does not affect Narcan, a spray version of the drug naloxone now sold by Emergent. That from is popular for police, firefighters and others to use to try to revive people who are overdosing. It is not subject to an exclusivity agreement on the spray technology. Narcan retails for about $140 for two doses, but the company sells that amount to first responders for $75. More than 400,000 deaths in the U.S. since 2000 have been linked to opioids, a class of drugs that includes heroin, fentanyl, and prescription painkillers such as Vicodin and OxyContin. Companies would still need Food and Drug Administration approval before their products could be on the market. There is at least one effort to introduce a generic version of a naloxone nasal spray. Purdue Pharma, the maker of OxyContin, announced a grant in 2018 for a nonprofit drug company to develop one. ___ This story has been updated to correct that the drug at the center of the agreement is a spray version of nalmefene that is under development, not naloxone. It also clarifies that Narcan is sold to first responders for a lower-than-retail price.
Example Output: Deal will let more companies make an overdose antidote spray.

Example Input: The delicacy, long a feature on the menu of gourmet restaurants across the globe, is made by force-feeding geese to turn their livers to fat, a process long denounced as cruel by animal rights activists and increasingly viewed with unease by authorities in some western cities. In October, New York City, often considered the U.S. fine dining capital, prohibited the sale of foie gras, following similar bans in Chicago and the state of California. In response, French scientists at research company Aviwell near Toulouse have developed an alternative version of the delicacy that uses bacteria - ingested by the goose as a serum - to stimulate a natural, rather than forced, build-up of fat. “It’s the combination of certain bacteria that is capable of triggering in baby geese the natural composition, and completely biological growth, of fat in the liver,” company co-founder Remy Burcelin said. Aviwell raised 600 geese when it launched its project last year, and Fosserie has now become the first foie gras farmer to adopt the technique, which also doubles the birds’ average lifespan from three to six months. “It’s the future, because we see the animal welfare movement getting bigger and bigger,” she said. This next-generation foie gras will be aimed primarily at the U.S. market and Europe, where Britain, Finland and Poland have banned its production. But the French culinary establishment is taking note too. Toulouse chef Simon Carlier, who has been creating dishes with Aviwell’s foie gras for a month, described it as subtle and with an appealing density. It could be served cold or just with little garnishing. “We see a texture, which is less nauseating, let’s say. We can’t compare it to meat - but in some way, it’s easier to eat,” Carlier said. It will also be more expensive. While high-quality traditional foie gras sells for about 300 to 400 euros  ($330-440) per kilo (2.2 lb), Aviwell’s version could fetch 1,000 euros. A naturally fatty goose liver weighs 300-400 grammas while that of a force-fed goose can weigh around 1 kg.
Example Output: Force-feeding off menu as France trials 'naturally fatty' foie gras.

Example Input: The panel voted 16 to 1 in favor of the drug, Northera, for patients with neurogenic orthostatic hypotension (NOH), a rare, chronic type of low blood pressure that occurs on standing and is associated with certain neurological disorders such as Parkinson’s disease. Chelsea shares more than doubled in after-hours trading. The FDA is not bound to follow the advice of its panels but typically does so. Panelists wrestled with gaps in the clinical data which they said made it difficult to determine whether the drug, which appears effective after one week’s treatment, is effective over the long term. Most suggested the company be required to conduct a follow-up study to prove a durable benefit. Dr. James de Lemos, a cardiologist and professor of medicine at the University of Texas Southwestern Medical Center, said he voted in favor “based on the compelling evidence of suffering and the absence of viable alternatives,” but said the approval should be conditional on further study. Patients and patient advocates testified before the panel about the positive impact the drug has had on their lives. Gail Hershkowitz, 65, a retired music teacher who lives in Boynton Beach, Florida, was diagnosed with Parkinson’s disease 15 years ago and, later, with NOH. She said in an interview that she became afraid to leave her house after fainting and vomiting multiple times in public. She took Northera as part of a clinical trial and says it has enabled her to lead a relatively normal life. But some panelists expressed frustration that the experience of patients who have benefited from the drug was not clearly backed up by data from the clinical trials. A reviewer for the FDA, Dr. Shari Targum, said in preparatory documents published on Friday that she did not think the data was strong enough to support approval. Chelsea’s shares fell as much as 36 percent following that review. They were halted during the panel meeting on Tuesday, and rose to $5.78 in after-hours trading from a close on Monday of $2.30  Northera, also known as droxidopa, is converted by the body into norepinephrine, a chemical messenger that sends signals to blood vessels and the heart to regulate blood pressure. Insufficient norepinephrine can lead to light-headedness and fainting upon standing. Chelsea originally filed for approval of droxidopa in 2011, based on a study known as 301. In February, 2012, an FDA advisory panel recommended approval of the drug, but the agency rejected it and asked for additional data. The company sought to address the FDA’s concerns using data from a different study known as 306B, but the FDA denied the request and said an additional trial would be needed. Chelsea appealed the decision, and in early 2013 the FDA agreed to accept a resubmission based on data from the 306B study, saying that while short-term data, if convincing, would be adequate for approval, a post-approval study could be required to prove the results were durable. Targum said the results of study 306B did not meet those criteria. Most panelists, however, said that while there was no convincing evidence that the drug provides a durable benefit, there was no convincing evidence to show that it does not show a benefit. “This is a terrible disease and there are no other effective medications,” said Dr. Vasilios Papademetriou, a cardiologist and professor of medicine at Georgetown University. Although the studies were not perfect, he said, “the data convinced me there is a long lasting benefit in some patients.”  Chelsea licensed rights to the drug outside Asia from Dainippon Sumitomo Pharma in 2006. It was introduced in Japan in 1989.
Example Output:
FDA advisory panel backs Chelsea Therapeutics drug.